Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.35 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932162 | 0.78 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL6533931 | 0.77 | — | — | |
| SCHEMBL931864 | 0.75 | HPGD (0.50) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL930734 | 0.75 | CA2 (0.45) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL932102 | 0.74 | AVPR2 (0.48) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL931417 | 0.74 | NOTUM (0.36) | NPC1RAB9ANOTUM | |
| SCHEMBL932450 | 0.72 | OXTR (0.47) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2090476 | 0.70 | KMT2A (0.57) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL931205 | 0.69 | POLB (0.39) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL2090240 | 0.66 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875615-B2 | 3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; treatment of male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, or premature ejaculation | PFIZER INC (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063064-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, PRLHR, KISS1R | NPC1 3617/4885RAB9A 3483/4885SMN1; SMN2 2465/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | NPC1 4238/4885RAB9A 2985/4885SMN1; SMN2 1147/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | NPC1 3617/4885RAB9A 3483/4885SMN1; SMN2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.